Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical Company Limites Announces Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2021

07/30/2021 | 02:00am EDT

Takeda Pharmaceutical Company Limited announced unaudited consolidated earnings results for the first quarter ended June 30, 2021. For the quarter, the company reported revenue was JPY 949,603 million against JPY 801,850 million a year ago. Operating profit was JPY 248,552 million against JPY 167,285 million a year ago. Net profit for the period was JPY 200,421 million against JPY 82,519 million a year ago. Basic earnings per share was JPY 128.02 against JPY 52.93 a year ago. Diluted earnings per share was JPY 127.27 against JPY 52.69 a year ago.


© S&P Capital IQ 2021
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
09/15TAKEDA PHARMACEUTICAL : U.S. FDA approves Takeda's lung cancer therapy
RE
09/15TAKEDA PHARMACEUTICAL : U.S. FDA approves Takeda's lung cancer therapy
RE
09/15TAKEDA PHARMACEUTICAL : Exkivity Wins FDA Approval for Treatment of Lung Cancer ..
MT
09/15TAKEDA PHARMACEUTICAL : EXKIVITY™ (mobocertinib) Approved by U.S. FDA as t..
BU
09/13Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO
RE
09/13TAKEDA PHARMACEUTICAL : Novavax Statement on Takeda Agreement to Provide 150 Mil..
AQ
09/07TAKEDA PHARMACEUTICAL : Response to the New Incident Announced by the Japanese M..
PU
09/07TAKEDA PHARMACEUTICAL : to Manufacture and Provide 150 Million Doses of Novavax'..
PU
09/07Takeda’s Responds to the New Incident Announced by the Japanese Ministry of H..
CI
09/06TAKEDA PHARMACEUTICAL : Japan to purchase 150 million doses of Takeda-produced N..
RE
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 387 B 30 953 M 30 953 M
Net income 2022 253 B 2 316 M 2 316 M
Net Debt 2022 3 472 B 31 738 M 31 738 M
P/E ratio 2022 23,3x
Yield 2022 4,83%
Capitalization 5 855 B 53 518 M 53 510 M
EV / Sales 2022 2,75x
EV / Sales 2023 2,62x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 723,00 JPY
Average target price 4 844,67 JPY
Spread / Average Target 30,1%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-0.85%53 518
JOHNSON & JOHNSON5.11%435 465
ROCHE HOLDING AG11.23%327 497
PFIZER, INC.21.46%251 011
NOVO NORDISK A/S49.16%231 607
ELI LILLY AND COMPANY38.43%211 895